New drug combo shows promise in advanced breast cancer trial
NCT ID NCT03964532
First seen Apr 20, 2026 · Last updated May 15, 2026 · Updated 5 times
Summary
This early-stage trial tests a two-step treatment for people with advanced breast cancer that cannot be cured by surgery or radiation. First, participants receive a drug called talazoparib alone, then both talazoparib and avelumab together. The main goal is to check safety and side effects, while also looking at how the drugs affect the immune system. About 24 adults with measurable tumors are taking part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MedStar Georgetown University Hospital
Washington D.C., District of Columbia, 20007, United States
-
University of Utah, Huntsman Cancer Institute
Salt Lake City, Utah, 84112, United States
Conditions
Explore the condition pages connected to this study.